04/03/2026
Congratulations to our co-founder Dr. Rabi Hanna, chairman of Pediatric Oncology at Cleveland Clinic, who has published two articles in The New England Journal of Medicine. Dr. Hanna is an internationally recognized clinical researcher in the field of transplant and gene therapy. His mission, like ours, is to always find new and better therapies to save and improve the lives of patients with life threatening disorders through innovation and bring new treatment.
๐งฌ ๐๐๐๐๐๐-๐๐๐ฌ๐๐๐ ๐๐๐ง๐ ๐๐๐ข๐ญ๐ข๐ง๐ ๐จ๐ ๐๐๐๐ ๐๐ง๐ ๐๐๐๐ ๐๐ซ๐จ๐ฆ๐จ๐ญ๐๐ซ๐ฌ ๐ญ๐จ ๐๐ซ๐๐๐ญ ๐๐ข๐๐ค๐ฅ๐ ๐๐๐ฅ๐ฅ ๐๐ข๐ฌ๐๐๐ฌ๐
Dr. Hanna is the lead author in this multi-center first-in-human gene editing therapy using CRISPR/Cas12 to treat patients with severe sickle cell disease. Treatment with reni-cel led to normalization of the total hemoglobin level and an increase in the percentage of fetal hemoglobin, with no vaso-occlusive events occurring in 27 of 28 patients after infusion.
๐ https://www.nejm.org/doi/full/10.1056/NEJMoa2415550
๐ฉธ ๐๐๐๐๐๐-๐๐๐ฌ๐๐๐ ๐๐๐ง๐ ๐๐๐ข๐ญ๐ข๐ง๐ ๐จ๐ ๐๐๐๐ ๐๐ง๐ ๐๐๐๐ ๐๐ซ๐จ๐ฆ๐จ๐ญ๐๐ซ๐ฌ ๐ญ๐จ ๐๐ซ๐๐๐ญ ฮฒ-๐๐ก๐๐ฅ๐๐ฌ๐ฌ๐๐ฆ๐ข๐
Dr. Hanna was the second author on a paper that reviewed a phase 1โ2, multicenter, open-label, single-group study of reni-cel in participants 18 to 35 years of age with transfusion-dependent ฮฒ-thalassemia. The participants received myeloablative conditioning with busulfan before reni-cel infusion.
Nine participants with transfusion-dependent ฮฒ-thalassemia (four ฮฒ0/ฮฒ0 or ฮฒ0/ฮฒ0-like and five nonโฮฒ0/ฮฒ0 genotypes) received reni-cel and were included in the analysis...All the participants had neutrophil and platelet engraftment by 42 days after infusion.
๐ https://www.nejm.org/doi/full/10.1056/NEJMoa2501277
